https://sputnikglobe.com/20211103/the-lancet-releases-paper-on-efficacy-of-russias-single-dose-vaccine-sputnik-light-1090438119.html
The Lancet Releases Paper on Efficacy of Russia's Single-Dose Vaccine Sputnik Light
The Lancet Releases Paper on Efficacy of Russia's Single-Dose Vaccine Sputnik Light
Sputnik International
The vaccine has been tested as a booster shot in a number of clinical trials around the world. So far, it has been authorised for use in over 15 countries... 03.11.2021, Sputnik International
2021-11-03T09:25+0000
2021-11-03T09:25+0000
2021-11-03T09:38+0000
russian direct investment fund (rdif)
russia
gamaleya research institute of epidemiology and microbiology
vaccine
the lancet
sputnik v vaccine
https://cdn1.img.sputnikglobe.com/img/07e5/0a/0d/1089890381_0:0:3073:1728_1920x0_80_0_0_ec6ec4890360e6303e654737ae6ae98d.jpg
The medical journal The Lancet has released the results of a trial for Russia's single-dose vaccine Sputnik Light.The Russian Direct Investment Fund (RDIF) stressed in a press release on Wednesday that the publication is further proof that Sputnik Light "demonstrates a high safety profile and induces a strong humoral and cellular immune response".The open label, prospective, non-randomised phase 1/2 trial was aimed to assess the safety, tolerability, and immunogenicity of the Sputnik Light vaccine. It was carried out at a single clinical site in Russia's St. Petersburg, involved 110 enrolled participants and was sponsored by the Russian Direct Investment Fund.Sputnik Light is a single-component COVID-19 vaccine (the first component of the Sputnik V vaccine) that has been authorised in more than 15 countries, with the registration process ongoing in a further 30 nations.Sputnik V is the world's first vaccine against COVID-19. It has shown 91.6 percent efficacy and has been approved for use in 70 countries, representing a total population of four billion people, or 50 percent of the world's populace.
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
russian direct investment fund (rdif), gamaleya research institute of epidemiology and microbiology, vaccine, the lancet, sputnik v vaccine
russian direct investment fund (rdif), gamaleya research institute of epidemiology and microbiology, vaccine, the lancet, sputnik v vaccine
The Lancet Releases Paper on Efficacy of Russia's Single-Dose Vaccine Sputnik Light
09:25 GMT 03.11.2021 (Updated: 09:38 GMT 03.11.2021) The vaccine has been tested as a booster shot in a number of clinical trials around the world. So far, it has been authorised for use in over 15 countries, with 30 more nations in the process of registering the jab.
The Russian Direct Investment Fund (RDIF) stressed in a press release on Wednesday that the publication is further proof that Sputnik Light "demonstrates a high safety profile and induces a strong humoral and cellular immune response".
The open label, prospective, non-randomised phase 1/2 trial was aimed to assess the safety, tolerability, and immunogenicity of the Sputnik Light vaccine. It was carried out at a single clinical site in Russia's St. Petersburg, involved 110 enrolled participants and was sponsored by the Russian Direct Investment Fund.
"Overall incidence of solicited adverse reactions was 74 (67.2%) of 110 participants. Some volunteers had several adverse events of different degrees of severity. Most of the registered, solicited systemic and local adverse reactions were mild (73 [66.4%]). Only 6 participants (5.5%) had adverse events of moderate grade in severity. No serious adverse events were reported", the study reads.
Sputnik Light is a single-component COVID-19 vaccine (the first component of the Sputnik V vaccine) that has been authorised in more than 15 countries, with the registration process ongoing in a further 30 nations.
Sputnik V is the world's first vaccine against COVID-19. It has
shown 91.6 percent efficacy and has been approved for use in 70 countries, representing a total population of four billion people, or 50 percent of the world's populace.
